New antibody specialist sets up shop outside Prague
Pilzen – German antibody drug development and discovery firm Affimed Therapeutics AG (Heidelberg) has spun-out all of its antibody discovery activities into a new Czech subsidiary – AbCheck s.r.o., which is located in Pilzen. While Affimed will focus its clinical development activities on its bispecific CD30 x CD13 antibody AFM13, which targets NK cells in non-Hodgkin lymphoma patients, AbCheck will concentrate on antibody screening and development services. The spin-out will provide access to three different fully-human antibody libraries covering about 1010 sequentially and structurally diverse antibodies, as well as a technology portfolio that covers all aspects of generation of therapeutic antibodies, from research to lead optimisation. All three libraries display human antibodies as scFv on the surface of phage particles, but differ in the generation of diversity. The new business will be led by former Affimed Chief Business Officer Volker Lang.